NO982894L - Polymere - Google Patents

Polymere

Info

Publication number
NO982894L
NO982894L NO982894A NO982894A NO982894L NO 982894 L NO982894 L NO 982894L NO 982894 A NO982894 A NO 982894A NO 982894 A NO982894 A NO 982894A NO 982894 L NO982894 L NO 982894L
Authority
NO
Norway
Prior art keywords
polymer
Prior art date
Application number
NO982894A
Other languages
English (en)
Norwegian (no)
Other versions
NO982894D0 (no
Inventor
Martin Charles Garnett
Fiona Caroline Maclaughlin
Stanley Stewart Davis
Fabio Bignotti
Paolo Ferruti
Original Assignee
Danbiosyst Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst Uk Ltd filed Critical Danbiosyst Uk Ltd
Publication of NO982894D0 publication Critical patent/NO982894D0/no
Publication of NO982894L publication Critical patent/NO982894L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Graft Or Block Polymers (AREA)
NO982894A 1996-01-06 1998-06-22 Polymere NO982894L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9600272.0A GB9600272D0 (en) 1996-01-06 1996-01-06 Polymers
PCT/GB1997/000022 WO1997025067A2 (en) 1996-01-06 1997-01-06 Polymers

Publications (2)

Publication Number Publication Date
NO982894D0 NO982894D0 (no) 1998-06-22
NO982894L true NO982894L (no) 1998-06-22

Family

ID=10786719

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982894A NO982894L (no) 1996-01-06 1998-06-22 Polymere

Country Status (8)

Country Link
US (1) US6413941B1 (de)
EP (1) EP0871491A2 (de)
JP (1) JP2000503645A (de)
AU (1) AU714937B2 (de)
CA (1) CA2241830A1 (de)
GB (1) GB9600272D0 (de)
NO (1) NO982894L (de)
WO (1) WO1997025067A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA978537B (en) 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
US6730735B2 (en) 1997-07-03 2004-05-04 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Conjugate of polyethylene glycol and chitosan
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
EP1063254A1 (de) * 1999-06-25 2000-12-27 Technische Uni München, Klinikum rechts der Isar, Inst. für Experiment. Onkoligie und Therapieforschung Copolymere für den Transport von Nukleinsäuren in die Zelle
WO2001000708A1 (de) * 1999-06-25 2001-01-04 Christian Plank Kombinationen zur einführung von nucleinsäuren in zellen
JP4659937B2 (ja) * 1999-11-19 2011-03-30 ナノキャリア株式会社 コア−シェル構造のポリイオンコンプレックスミセル
WO2001066149A2 (en) * 2000-03-03 2001-09-13 Valentis, Inc. Nucleic acid formulations for gene delivery and methods of use
GB0009201D0 (en) * 2000-04-14 2000-05-31 Univ Nottingham Cationic polymer - Nucleic acid complexes and methods of making them
US7189705B2 (en) * 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
DK1301213T3 (en) * 2000-07-21 2017-03-27 Revance Therapeutics Inc MULTI-COMPONENT SYSTEMS FOR BIOLOGICAL TRANSPORT
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
ATE292144T1 (de) 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
CA2513072A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
CN101239190B (zh) * 2003-01-27 2013-09-25 恩多塞特公司 维生素受体结合递药缀合物
JP4763459B2 (ja) * 2003-05-29 2011-08-31 株式会社東京大学Ｔｌｏ 安定化高分子ミセル
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
HUE025656T2 (en) * 2004-03-03 2016-04-28 Revance Therapeutics Inc Topical application and transdermal delivery of botulinum toxins
US8399025B2 (en) * 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
ES2362301T3 (es) 2005-03-03 2011-07-01 Revance Therapeutics, Inc. Composiciones y procedimientos para aplicaciones tópicas y liberación transdérmica de un oligopéptido.
KR20070110402A (ko) 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
KR100732013B1 (ko) * 2005-03-18 2007-06-25 성균관대학교산학협력단 ｐＨ 민감성 블록 공중합체 및 이를 이용한 고분자 마이셀
KR100665672B1 (ko) 2005-04-13 2007-01-09 성균관대학교산학협력단 새로운 온도 및 ｐＨ 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔
WO2007059528A2 (en) * 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
GB2439777B (en) * 2006-06-19 2012-01-25 Envirogene Ltd A method of tracing movement of a liquid
US20100021502A1 (en) * 2006-12-28 2010-01-28 Waugh Jacob M Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
WO2008082889A2 (en) * 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from hiv-tat
NZ598159A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Transport molecules using reverse sequence hiv-tat polypeptides
WO2009062084A2 (en) * 2007-11-07 2009-05-14 University Of Utah Research Foundation Cleavable modifications to reducible poly(amido ethylenimine)s to enhance nucleotide delivery
GB0724253D0 (en) 2007-12-12 2008-01-30 Fermentas Uab Transfection reagent
US9856456B2 (en) 2009-10-12 2018-01-02 Thermo Fisher Scientific Baltics Uab Delivery agent
SMT201900342T1 (it) 2012-03-15 2019-07-11 Acraf Polimeri cationici a base di glicogeno
EP3031447B1 (de) * 2013-08-06 2019-12-25 Japan Science and Technology Agency Polymermizellenkomplex zur nukleinsäureeinkapselung und verfahren zur herstellung davon
US9890094B2 (en) 2015-03-03 2018-02-13 Uop Llc High meso-surface area and high acid site density pentasil zeolite for use in xylene conversion
US10010878B2 (en) 2015-03-03 2018-07-03 Uop Llc High meso-surface area, low Si/Al ratio pentasil zeolite
US9643897B2 (en) 2015-03-03 2017-05-09 Uop Llc Enhanced propylene production in OTO process with modified zeolites
US10336665B2 (en) 2015-03-03 2019-07-02 Uop Llc Yields in xylene isomerization using layer MFI zeolites
IT201600081360A1 (it) * 2016-08-02 2018-02-02 Alfa Cm Srl Poliammidoammine ad attività antimicrobica

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1019525B (it) * 1972-03-21 1977-11-30 Ferdinando D Metodo apparecchio e prodotto per formare complessi stabili di polia nioni
US4093677A (en) * 1975-06-10 1978-06-06 Paolo Ferruti Macromolecular materials suitable for forming antithrombogenic prosthesis and artificial organs and process for preparing same
JPH08501097A (ja) * 1992-09-04 1996-02-06 ザ ゼネラル ホスピタル コーポレーション 臨床診断及び治療用部分を含む生体適合性ポリマー
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5717166A (en) * 1994-10-24 1998-02-10 Pitney Bowes Inc. Method for combining transducer outputs
US5783178A (en) * 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions

Also Published As

Publication number Publication date
JP2000503645A (ja) 2000-03-28
EP0871491A2 (de) 1998-10-21
WO1997025067A2 (en) 1997-07-17
NO982894D0 (no) 1998-06-22
CA2241830A1 (en) 1997-07-17
AU1386697A (en) 1997-08-01
WO1997025067A3 (en) 1997-09-18
AU714937B2 (en) 2000-01-13
US6413941B1 (en) 2002-07-02
GB9600272D0 (en) 1996-03-06

Similar Documents

Publication Publication Date Title
NO982894D0 (no) Polymere
EP0954547A4 (de) Epoxy-polysiloxan polymerzusammensetzung
DE69941841D1 (de) Polymere anordnungen
NO991190D0 (no) Polymerisasjonskatalysator
BR9707663A (pt) Compósito de polímero
DE59814236D1 (de) Photovernetzbare Polymere
DE69723100D1 (de) Poröse polyorganosiloxanpolymere
PT1019090E (pt) Derivados polimeros de camptotecina
NO975894L (no) Foringsr°rpakning
DE69831912D1 (de) Biokompatible polymere
DE59611221D1 (de) Polymere schäume
DE69516101D1 (de) Vernetzte Polymere
DE69707712D1 (de) Polymere enthaltend hochgepfropftkautschuk
NO996435D0 (no) Polymerisasjonsprosess
NO20000014D0 (no) Grohemmende polymerer
DE59709953D1 (de) Photoadressierbare Seitengruppenpolymere
NO973710D0 (no) Polymerisasjonsprosess
DE69624968D1 (de) Vernetzte Polymere
NO973709D0 (no) Polymerisasjonsprosess
DE69804145D1 (de) Leitfähige Polymere
ATE220411T1 (de) Polymerentgasung
DE59705833D1 (de) Biaxialmischer
DE69618180D1 (de) Mannichbase polymere
EP0791019A4 (de) Kationisches polymer
NO20003168D0 (no) Polymerisasjonsmetode

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application